Does elevated homocysteine cause endothelial dysfunction and increase cardiovascular risk?

Mechanistic pathways

Elevated homocysteine (Hcy) impairs endothelial function through multiple overlapping biochemical pathways that culminate in reduced nitric oxide (NO) bioavailability:

• Oxidative stress induction: Hcy upregulates NADPH oxidases (particularly NOX2), triggering the generation of superoxide radicals that rapidly react with NO to form peroxynitrite ($ONOO^-$). This scavenging of NO severely blunts flow-mediated, NO-dependent vasodilation.
• eNOS uncoupling: Under chronic hyperhomocysteinemia, oxidative depletion of the essential cofactor tetrahydrobiopterin ($BH_4$) leads to the uncoupling of endothelial nitric oxide synthase (eNOS). Once uncoupled, eNOS switches from producing beneficial NO to generating superoxide, establishing a pro-oxidant feed-forward loop.
• Methylation and ER stress: Hcy accumulation disrupts cellular methylation pathways by elevating S-adenosylhomocysteine (AdoHcy), which induces a hypomethylating environment that suppresses eNOS protein expression. Additionally, Hcy-induced endoplasmic reticulum (ER) stress activates the unfolded protein response, promoting endothelial cell apoptosis and inflammatory activation.

Clinical and epidemiological evidence

Large-scale prospective cohort studies and meta-analyses consistently link elevated homocysteine levels to an increased risk of cardiovascular disease (CVD) and mortality:

• Graded observational risk: Meta-analyses of prospective studies in the general population demonstrate a strong, graded relationship, showing that a 5 µmol/L increase in homocysteine correlates with significantly higher coronary heart disease (CHD) and cardiovascular mortality risks.
• Sex differences: Sex-stratified analyses indicate that the observational association between homocysteine and cardiovascular risk may be stronger and more consistently significant in men than in women, potentially due to lower baseline metabolic burden or estrogenic protection in premenopausal women.
• Causality and intervention discrepancy: Despite the robust observational association and clear mechanistic pathways of endothelial injury, large-scale Mendelian randomization studies and B-vitamin intervention trials (e.g., folic acid, B6, and B12 supplementation) have failed to demonstrate a causal link. While B-vitamins successfully lower plasma homocysteine levels, they do not reduce major cardiovascular events or overall mortality.

Bottom line

Elevated homocysteine is a well-established observational predictor of increased cardiovascular risk and a proven contributor to endothelial dysfunction via oxidative stress, eNOS uncoupling, and cellular methylation defects. However, because lowering its levels does not reduce cardiovascular events, it acts as a valuable risk marker of underlying vascular or renal pathology rather than a direct, modifiable therapeutic target.